This Teradyne Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Wall Street analysts changed ratings for top stocks. See full list at Benzinga's analyst ratings page. TER, TX and more.
Read original at benzingaStocks · News reference
Health Catalyst Q2 Adj. EPS $0.04 Beats $0.03 Estimate, Sales $70.487M Beat $69.059M Estimate
Health Catalyst (NASDAQ:HCAT) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $0.03 by 33.33 percent. This is unchanged from the same period last year. The company reported
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 6, 2026, 8:04 PM
- Checked
- Aug 6, 2026, 8:04 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Canaccord Genuity Downgrades Health Catalyst to Hold, Lowers Price Target to $1.8
Canaccord Genuity analyst Richard Close downgrades Health Catalyst (NASDAQ:HCAT) from Buy to Hold and lowers the price target from $3 to $1.8.
Read original at benzingaWells Fargo Maintains Equal-Weight on Health Catalyst, Lowers Price Target to $1.5
Wells Fargo analyst Stan Berenshteyn maintains Health Catalyst (NASDAQ:HCAT) with a Equal-Weight and lowers the price target from $1.75 to $1.5.
Read original at benzingaCitigroup Maintains Neutral on Health Catalyst, Lowers Price Target to $2
Citigroup analyst Daniel Grosslight maintains Health Catalyst (NASDAQ:HCAT) with a Neutral and lowers the price target from $2.5 to $2.
Read original at benzinga